CL2021000744A1 - Métodos para tratar trastornos mieloproliferativos - Google Patents

Métodos para tratar trastornos mieloproliferativos

Info

Publication number
CL2021000744A1
CL2021000744A1 CL2021000744A CL2021000744A CL2021000744A1 CL 2021000744 A1 CL2021000744 A1 CL 2021000744A1 CL 2021000744 A CL2021000744 A CL 2021000744A CL 2021000744 A CL2021000744 A CL 2021000744A CL 2021000744 A1 CL2021000744 A1 CL 2021000744A1
Authority
CL
Chile
Prior art keywords
methods
myeloproliferative disorders
treat myeloproliferative
treat
disorders
Prior art date
Application number
CL2021000744A
Other languages
English (en)
Spanish (es)
Inventor
John Hood
Tymara Berry
Catriona Jamieson
Curtis L Scribner
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021000744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CL2021000744A1 publication Critical patent/CL2021000744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CL2021000744A 2018-09-25 2021-03-25 Métodos para tratar trastornos mieloproliferativos CL2021000744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US201862783076P 2018-12-20 2018-12-20

Publications (1)

Publication Number Publication Date
CL2021000744A1 true CL2021000744A1 (es) 2021-10-08

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000744A CL2021000744A1 (es) 2018-09-25 2021-03-25 Métodos para tratar trastornos mieloproliferativos

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) * 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
US20240058336A1 (en) 2020-12-16 2024-02-22 Impact Biomedicines, Inc. Dosing of fedratinib
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3099677A4 (en) * 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN108348578B (zh) * 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Also Published As

Publication number Publication date
WO2020068755A1 (en) 2020-04-02
MX2023013844A (es) 2023-12-08
JP2024161416A (ja) 2024-11-19
AU2019346521A1 (en) 2021-05-20
JP2022502492A (ja) 2022-01-11
SG11202103019WA (en) 2021-04-29
EP3856169A1 (en) 2021-08-04
KR20250164332A (ko) 2025-11-24
MY209349A (en) 2025-07-03
EP3856169A4 (en) 2022-06-29
AU2019346521B2 (en) 2025-05-08
BR112021005518A2 (pt) 2021-06-29
IL281736A (en) 2021-05-31
MX2021003450A (es) 2021-07-16
US11400092B2 (en) 2022-08-02
MA53741A (fr) 2021-08-04
US20220133724A1 (en) 2022-05-05
CN113286584A (zh) 2021-08-20
KR20210102192A (ko) 2021-08-19
US20220031699A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
CL2021000744A1 (es) Métodos para tratar trastornos mieloproliferativos
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ECSP18089579A (es) Moduladores de la vía de estrés integrada
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
SA521421845B1 (ar) منتجات مضادة للفيروسات وصيغ نانوية منها
UY37230A (es) Moduladores de la vía de estrés integrada
UY37231A (es) Moduladores de la vía de estrés integrada
MX2016014140A (es) Composiciones y metodos para modular la expresion de pkk.
UY37229A (es) Moduladores de la vía de estrés integrada
EP4454707A3 (en) Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
UY37018A (es) Inhibidores bicíclicos de pad4
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
MX2015017253A (es) Composiciones y metodos para tratar trastornos metabolicos.
EP4523757A3 (en) Compositions and methods for treating pathological calcification and ossification
CL2018001714A1 (es) Reguladores del cftr y métodos para su uso
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
BR112017025263A2 (pt) método para o tratamento de doença neurológica